CASI Pharmaceuticals Appoints James Huang to Board of Directors (Form 6-K)

CASI Pharmaceuticals Appoints James Huang to Board of Directors

South San Francisco, California / September 26, 2025 / ACCESS NEWSWIRE / -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced the appointment of James Huang as an Independent Director to the CASI Board of Directors, effective as of October 1, 2025.

Mr. Huang brings over 35 years of experience building and investing in biopharma companies globally. As Founder and Managing Partner of Panacea Venture, and previously Managing Partner at Kleiner Perkins (KPCB) China and Vivo Ventures, he has guided numerous cross-border companies through critical stages of growth, financing, and global expansion. Earlier in his career, he held senior roles in business development, sales & marketing, and research & development at Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Myers Squibb and ALZA Corp. (acquired by Johnson & Johnson). Mr. Huang serves as a member of the board of directors of Kindstar Globalgene Technology, Inc., Connect Biopharma Holdings Limited, Lee's Pharmaceutical Holdings Limited, Atara Biotherapeutics, Inc., and several private companies. He received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley.

"I am honored to join the CASI Board as the company embarks on a pivotal new chapter with a sharpened U.S. focus and a commitment to rapidly advance clinical development of CID-103 in autoimmune diseases and antibody-mediated rejection in solid organ transplants," said Mr. Huang. "I look forward to partnering with company leadership to bring strategic perspective, principled governance, and long-term alignment with shareholders as CASI establishes itself as a U.S.-centric clinical-stage leader in autoimmune and transplant medicine."

David Cory, CEO of CASI, added, "As our CID-103 anti-CD38 program progresses in the clinic and delivers data across diverse patient populations and indications, we expect James' global perspective and proven ability to scale companies will be invaluable. I am very pleased to welcome James to our Board and look forward to working closely with him as we drive CASI toward its next phase of growth."

Panacea Venture is a current CASI Pharmaceuticals shareholder and, in connection with Mr. Huang's appointment to the Board, plans to acquire up to approximately 1.5 million newly issued shares of CASI Pharmaceuticals common stock from CASI in a registered transaction.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a publicly-traded, biopharmaceutical company focused on developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases.

CID-103 is a fully human IgG1, potentially best-in-class, clinical stage, anti-CD38 monoclonal antibody which targets a unique epitope and has demonstrated an encouraging pre-clinical efficacy and clinical safety profile compared to other anti-CD38 monoclonal antibodies, and for which CASI owns exclusive global rights. CASI is actively recruiting and dosing patients in a Phase 1 / 2 study in immune thrombocytopenic purpura (ITP). In parallel, CASI recently received FDA IND clearance to conduct a Phase 1/2 study in renal allograft antibody-mediated rejection (AMR) with plans for first patient in Q1 2026.

Pursuant to a May 2025 announcement that CASI had entered into an equity and asset transfer agreement with Kaixin Pharmaceuticals to divest CASI China business, the company plans to complete divestiture in Q2 2026.

More information on CASI is available at www.casipharmaceuticals.com.